tbuckley/cabot-search huggingface dataset:
POS1312 ANALYSIS OF INTERFERON TYPE I SIGNATURE IN JUVENILE DERMATOMYOSITIS
Authors: R. Raupov, E. Suspitsin, R. Mulkidzhan, M. Kostik
Journal: Annals of the Rheumatic Diseases (2022)

Background the crucial role of hyperactivation IFN I signaling pathway has been proved in the pathogenesis of dermatomyositis. IFN I genes and chemokines activity vary according to subtype of inflammatory myopathies. IFN type 1 signature could be measured using different genes in the blood, skin and muscle tissue [1]. Objectives to evaluate IFN-score in children with dermatomyositis and compare with disease activity Methods 15 patients (5 boys and 10 girls) were enrolled in the study. Clinical and laboratory parameters, disease activity (CMAS-childhood myositis assessment tool, aCAT- abbreviated cutaneous assessment tool) and treatment were assessed. Patients were compared accordingly to IFN-score elevation. IFN I-score was assessed by RT-PCR quantitation of 5 IFN I-regulated transcripts (IFI44L, IFI44, IFIT3, LY6E, MXA1); median relative expression of ≥ 2 was considered as a cut-off. IFN I-score was evaluated in dynamics in 9 patients. Results median age of patients was 6.2 (3.6; 7.6) years. Skin and muscle involvement were in all patients, arthritis in 5 (33%) patients, calcinosis in 3 (20%), lipodystrophy in 2 (13%) and lung involvement in 5 patients (33%), and 9 patients (60%) had positive myositis-related antibodies. Ten patients (67%) had an active disease, while elevated IFN-signature was detected in 12 (80%) patients. Cumulative IFN I-score and its’ five components were higher in active patients, compare to inactive (13.6 vs 1.4, p=0.006). Patients with increased IFN I-score had lower CMAS score and higher aCAT score compare to patients with normal levels of IFN I-score. IFN-I score correlated with aCAT, arthritis and lung involvement. Conclusion IFN-I score may be considered as disease activity biomarker in juvenile dermatomyositis with predominantly skin activity process. References [1]Rigolet M, Hou C, Baba Amer Y, Aouizerate J, Periou B, Gherardi RK et al. Distinct interferon signatures stratify inflammatory and dysimmune myopathies. RMD Open. 2019 Feb 26;5(1):e000811. doi: 10.1136/rmdopen-2018-000811. PMID: 30886734; PMCID: PMC6397431. Acknowledgements This work was supported by the RSF grant № 20-45-01005 Disclosure of Interests None declared
AB1221 START BACK TOOL RISK SCORE: WHAT GUIDANCE TO GIVE IN A MILITARY LOW BACK PAIN POPULATION?
Authors: R. Dhahri, W. Lahmar, O. Dhrif, M. Slouma, L. Metoui, I. Gharsallah, K. Amri, Y. Mallat, L. Nouisri
Journal: Annals of the Rheumatic Diseases (2022)

Background The Keele start back Tool (SBT) is a 9-item self-reported questionnaire validated to identify individuals with non-specific low back pain (LBP) who have prognostic factors for persistent disabling pain. Thus, it is a useful component of stratified care, where patients’ prognostic subgroups are matched with appropriate treatment. Objectives The aim of our study was to report the prevalence of SBT-calculated risk for back pain disability in Tunisian military patients. Methods It was a cross sectional study. The SBT questionnaire was administered to patients &gt; 18 years presenting with common low back pain in outpatient Military teaching hospital in Tunis, Tunisia (from January to Mars 2021). The normality of data distribution was checked by the Kolmogorov-Smirnov test. Quantitative variables were presented as mean ± standard deviation (SD) or median (interquartile range), as appropriate. The categorical variables were expressed as percentages. Results Out of 114 participants; the mean age at diagnosis was 79 +/- 12 years old, sex ratio was equal to 1, the median of symptom duration was 22 (6-36) months, 83 (72.8%) were employed, 54 (47.4%) were on active military duty. Comorbidities reported in our patients were distributed as followed: 52 (45.6%) cases of overweight, 21 (18.4%) cases of obesity, 17 (14.9%) had hypertension, 13 (11.4%) suffered from type 2 diabetes, 10 (8.8%) had dyslipidemia, 6 (5.3%) cases of hypothyroidism and 3 (2.6%) cases of auto-immune diseases. Seventy (61.4%) participants reported anxious thoughts, 75 (65.8%) patients expressed avoidance beliefs, 59 (51.8%) patients mentioned catastrophizing thoughts and 50 (43.9%) were dealing with low mood. Mean SBT psychological score was at 2.68 +/-1.5. Patients reported a mean SBT score of 5.31+/-2.1 with the following risk stratification: 27 (23.7%) scored low-risk, 47 (41.2%) medium risk, and 40 (35.1%) high-risk. Conclusion This is the first study to report the prevalence of SBT-designated risk subgroups among Tunisian population. Medium or high-risk scores for back pain disability were more prevalent the surveyed sample. Also, rates of low mood and anxious thoughts indicate a need for future research to explore psychosocial factors in non-specific low back pain. Disclosure of Interests None declared
POS1538-HPR INVESTIGATION OF BALANCE FUNCTIONS IN INDIVIDUALS WITH NEURO-BEHCET: A PILOT STUDY
Authors: S. Yenil, E. Gur Kabul, F. Ulutas, B. Basakci Calik, V. Cobankara
Journal: Annals of the Rheumatic Diseases (2022)

<h3>Background</h3> Behcet's disease is a vasculitis, causing multisystem inflammation and resulting in oral and genital ulcers and eye and skin lesions (1). A proportion of patients also have neurological involvement, termed Neuro-behcet's disease (2). We think about that Neuro-behçet's disease can impact balance functions in patients due to neurological involvement. However, there is no study investigating the balance functions in patients with Neuro-behcet. <h3>Objectives</h3> To investigate the balance functions in individual with Neuro-behçet's disease. <h3>Methods</h3> In this study 8 Neuro-behcet patients with a mean age of 38.37±16.96 who were followed in the PAU Rheumatology outpatient clinic and diagnosed by a rheumatologist according to the criteria of the International Behcet Study Group and 8 healthy control with a mean age of 42.62±13.94 with similar demographic characteristics were included. Exclusion criteria for the study were age &lt;18 years old, having any disease which mimics BD (including systemic lupus erythematosus, vasculitis of central nervous system). Demographic data of the participants were recorded. Then, balance functions were evaluated with a balance board (Sensamove MaxiBoard, NL) in Neuro-behcet and control groups. This assesment included static balance, proprioception, and reaction. Results were analyzed with Mann Whitney U Test. <h3>Results</h3> Participants were similar in terms of age and gender (p&gt;0.05). Neuro-behcet group showed a significant decrease in static balance in all directions except the right side compared to the control group (p&lt;0.05). A significant decrease was observed in the right and left reaction times in Neuro-behcet group compared to control group (p&lt;0.05). There was no significant difference between the two groups in proprioception assesment (p&gt;0.05). <h3>Conclusion</h3> This results show that patients with Neuro-behcet may experience disturbances in static balance and reaction time. Balance and reaction exercises should be included in rehabilitation. Further research is needed on the effect of balance functions and the effectiveness of balance exercises in Neuro-behcet's disease. <h3>References</h3> [1]The International Criteria for Behçet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2014;28(3):338-47. [2]Borhani-Haghighi A, Kardeh B, Banerjee S, Yadollahikhales G, Safari A, Sahraian MA, ve ark. Neuro-Behcet's disease: An update on diagnosis, differential diagnoses, and treatment. Multiple Sclerosis and Related Disorders. 2020;39:101906. <h3>Disclosure of Interests</h3> None declared
AB0866 Women spondyloarthritis: epidemiological, clinical and paraclinical characteristics
Authors: H. Bara, H. Arabi, A. Rafi, A. Mougui, I. El Bouchti
Journal: Annals of the Rheumatic Diseases (2022)

Background Spondyloarthritis (SPA) is a chronic inflammatory rheumatism characterized by sacroiliitis and spinal involvement, affecting both genders but more frequent in males. Objectives The aim of this study is to analyze the epidemiological, clinical and paraclinical characteristics of Spondyloarthritis in women. Methods Retrospective study included 333 patients followed up for SPA at the Rheumatology Department between 2004 and 2021. Results Our study involved 153 women and 180 men. In the female population, the mean age was 45.1 years, 12.4% had high blood pressure, 4.8% had a psychiatric comorbidity and none of the patients were smokers, versus a mean age of 36.4 years, 5% of high blood pressure’s patients, 1.7% having a psychic comorbidity and 25% of the smokers for the male with SPA. The age of onset of symptoms was 36.5 years for women versus 28 years for men (p =0.001). Axial involvement was 84.3% in women and 85% in men, while peripheral and enthesial involvement was present in 73.8% and 56.8% of female subjects and 58.8% and 46.6% of male subjects (p at 0.004 and 0.064 respectively). Coxitis was present in 13.1% and syndesmophytis in 15.3% of females versus 36.1% and 18.3% of males (p at 0.001 and 0.4 respectively). Mean erythrocyte sedimentation rate was 45.7, mean CRP 28.5 and mean calcemia 92 in the 1st group versus 43, 40.6 and 93.4 in the 2nd (p at 0.4; 0.03 and 0.03 respectively). Relapse was 26.8% in female with SPA and 12.6% in male (p =0.025) Conclusion In our study, females SPA patients developed symptoms later than did males, peripheral and enthesial involvement is more common in females while coxitis is more common in males with statistically significant higher CRP and calcemia. References [1]Rusman T, van Vollenhoven RF, van der Horst-Bruinsma IE. Gender Differences in Axial Spondyloarthritis: Women Are Not So Lucky. Curr Rheumatol Rep. 2018 Jun;20(6). [2]Sboul S, Nassar K, Janani S. La spondylarthrite féminine: particularités cliniques et paracliniques. Revue du Rhumatisme. 2021 Dec;88:A266. Disclosure of Interests None declared
POS0960 INCIDENCE AND RISK OF OVERALL INFECTIONS IN PATIENTS WITH ANKYLOSING SPONDYLITIS RECEIVING BIOLOGIC THERAPIES: A REAL-WORLD PROSPECTIVE OBSERVATIONAL STUDY USING KOBIO REGISTRY
Authors: K. M. Ko, S. J. Moon
Journal: Annals of the Rheumatic Diseases (2022)

Background Infection is a perpetual concern in patients treated with biological therapy. However, long-term real-world data on infectious profile of AS patients are lacking. Objectives The aim of this study was to characterize infection events in a longitudinal cohort of patients with ankylosing spondylitis (AS) and to identify the risk factors associated with the development of infections receiving biologics therapies in a real-world setting. Methods This was a prospective observational cohort study including AS patients in the KOBIO registry starting a biologics from December 2012 to April 2020. Infections were evaluated by types or organ during the follow-up period. Infection rates (IR) per 1,000 person-years were calculated with 95% CI based on Poisson distribution method. Cox proportional hazard regression models with adjustment of confounding factors was used to estimate hazard ratios (HRs) with 95% CIs for occurrence of infection. Confounders included demographics, comorbidities and disease severity index. Results A total of 1610 AS patients were included in the analysis. Most (76.8%) were men and the median age was 37 years with 5.73 median AS duration. 129 infection events occurred during 5020.5 person-years of follow-up. The most frequent infections were upper and lower respiratory tract (39.8%), followed by herpes zoster (23.7%), skin and soft tissue (except herpes infection), gastrointestinal tract, and genitourinary tract. The overall incidence of any infection was 25.7/1000 patient-years (PY) of follow-up (95% confidence interval [CI] 21.5 - 30.5): 29.5/1000 PY (95% CI 20.6 – 41.1) among those treated with infliximab and biosimilar; 26.8/1000 PY (95% CI 20.1 – 34.9) among those treated with adalimumab; 21.5/1000 PY (95% CI 14.1 -31.6) among those treated with golimumab; 17.8/1000 PY (95% CI 9.5 -30.5) among those treated with etanercept and biosimilar.; 81.1/1000 PY (95% CI 2.1 – 451.9) among those treated with secukinumab. Significant univariate risk factors for infection were age, ischemic heart disease, complicated diabetes, solid tumor, abnormal chest x-ray, anemia, and biologics user. In multivariate Cox regression model, ischemic heart disease, very high disease activity (ASDAS-ESR&gt;3.5), complicated diabetes, abnormal chest x-ray and current biologics users remained significant. Conclusion In the KOBIO-AS registry, the total incidence rate of infections was 26 events/1000 PY of follow-up, with respiratory infection being the most common, followed by herpes zoster infection. In this large cohort of AS patients, ischemic heart disease, very high disease activity (ASDAS-ESR&gt;3.5), complicated diabetes, abnormal chest x-ray and current biologics user were risk factors for any infection in this large cohort of patients with AS, whereas male gender was protective factor for developing infection. Disclosure of Interests None declared
AB0049 ASSOCIATION WITH LEPTINEMIA AND Q223R (rs1137101) POLYMORPHISM OF LEPR GENE IN FEMALE PATIENTS WITH KNEE OSTEOARTHRITIS
Authors: L. Shvets, V. Novoseletskyi, V. Khomenko, L. Perebetiuk, M. Stanislavchuk
Journal: Annals of the Rheumatic Diseases (2022)

Background Knee Osteoarthritis is the most common form of arthritis, affecting millions of people worldwide. Poor early diagnostics, growing share of seniors in the population structure, the need for genetic or other molecular biomarkers to improve safety, efficacy, and outcome of treatment of OA patients make up the key issues of scientific interest. Objectives To assess the association between serum leptin concentrations, the LEPR gene Q223R(rs1137101 ) polymorphism in patients with knee OA. Methods The participants in this study (knee OA patients = 99, control group (healthy women) = 62) underwent blood measurement to LEPR Q223R(rs1137101 ) genotyping assay and leptin serum levels. We analyzed the relationship with multivariate regression models using generalized linear models with binomial link function. Results In this way, allele frequency and genotypic variant specificity for polymorphic variant Q223R(rs1137101) of LEPR gene in women with OA of knee joints were determined. The frequency of the variant allele G(Arg) in the group of patients with OA of the knee joints was 0.54 and in the control group 0.43. The results were unreliable, although the nature of the trend was small (p = 0.06). In patients with OA, the genotype Q223R(rs1137101) of the LEPR gene was significantly subdivided according to the Hardy-Weinberg law (p = 0.002), which was due to the higher frequency of homozygotes of both types, while theoretically scoring with the same status. The association of the Q223R(rs1137101) polymorphism of the LEPR gene with the risk of developing OA of the knee joints in the recessive model of decay (GG/AA + AG) was revealed: odds ratio (OR) = 2.15 (95% CI: 1.03-4.50), p = 0.04. There was no correlation between the Q223R(rs1137101) polymorphism of the LEPR gene and such clinical and laboratory indicators as clinical form, body mass index, and blood serum leptin concentration. Carriers of AG (Gln/Arg) + GG(Arg/Arg) genotypes have a significantly higher risk of developing rapid X-ray progression of OA (II and III X-ray stages, due to I) after 5 years of diseases: OR = 5.17 (95% CI: 1.04 - 25.57), р = 0.03. Conclusion Our results suggest that the patients with knee OA the AG (Gln/Arg ) and GG (Arg/Arg ) genotype carriers have statistically significant higher risk of OA. Further study of this issue is needed. Disclosure of Interests None declared
AB1224 NON-CONTIGUOUS MULTIFOCAL SPONDYLODISCITIS: A RETROSPECTIVE OBSERVATIONAL STUDY
Authors: S. Rekik, S. Boussaid, Z. Zeineb, S. Jemmali, S. Rahmouni, K. Zouaoui, H. Sahli, M. Elleuch
Journal: Annals of the Rheumatic Diseases (2022)

Background Non-contiguous multifocal spondylodiscitis (mSpD) is a serious infection. Although literature data highlight the opportunity to miss a non-contiguous spondylodiscitis (SpD), recommendations for which cases an MRI of the entire spine should be performed are missing. Objectives The aim of the study was to assess the clinical features of mSpD to reveal risk factors underlining the need for screening a multifocal spine involvement Methods We retrospectively evaluated the data of patients with confirmed non-contiguous multifocal spondylodiscitis Results Twelve patients suffered from mSpD were included (6 males, 6 females). The mean age was 60 years. Four patients had underlying chronic comorbidity, Diabetes (n=3), hepatitis C virus (n=1). Most patients had spine pain (11 patients,), radiculalgia in one patient, neurologic deficit (3 patients), worsening health status (7 patients). Symptoms onset was acute (n=1) or sub-acute (n=3) or long term (n=8) before admission. The mean duration between the diagnosis and the onset on symptoms was 9,6 months. Tubercular spondylodiscitis was the most detected etiology (n=8), confirmed by histological analysis (n=3) then brucellar, confirmed by serlology lab test, and pyogenic SpD in two patients each. Non-contiguous multi-level involvement in the lumbar, thoracic, and cervical spine was detected in one patient for each region. Seven patients suffered from a lumbar and thoracic spine involvement and SpD occurs in the three regions in two patients. Elevated inflammatory biomarkers (CRP and ESR) were present in all cases. Entire spine MRI was performed for almost all patients, confirmed the diagnosis, showed para-vertebral abscess (n=3), epidural inflammation (n=6), and spinal cord compression (n=3). The majority of cases showed a favorable evolution with appropriate antibiotic therapy. One patient maintain a neurologic deficit, and one suffered from a severe degree of pain. Surgical approach was not indicated. Conclusion In our study, mSpD did not appear to be associated with a particular pattern. Tuberculosis was the dominant etiology. That suggests, an MRI of the entire spinal column should be performed for each patient with suspicious SpD, especially when tuberculosis is evocated Disclosure of Interests None declared
POS1175 IMPACT OF COVID-19 ON THE CLINICAL COURSE OF GOUT AND THE OVERALL USAGE OF MEDICATION IN PATIENTS WITH GOUT
Authors: S. Smiyan, O. Makhovska
Journal: Annals of the Rheumatic Diseases (2022)

Background Data on the course and outcomes of the coronavirus disease 2019 (COVID-19) in patients with gout are scarce, as gout is underrepresented in leading COVID-19 and rheumatological scientific publications [1]. Objectives To describe clinical changes, quality of life, therapy of gout before and after COVID-19, and the clinical course of severe acute respiratory syndrome-related coronavirus 2 (SARS-Cov-2) infection in the cohort of patients with gout. Methods In total, 84 males with gout were examined before the pandemic, during COVID-19 (March 2020 to December 2021) and 6 months after SARS-Cov-2 infection. The severity of COVID-19 in our cohort was determined. We conducted a comparative analysis of clinical and laboratory data, Gout Activity Score (GAS), urate-lowering (UST) and symptomatic therapy, Physical Component Summary (PCS) and Mental Component Summary (MCS) of the Short Form 36 (SF-36) Health Survey Questionnaire. Statistical difference of qualitative indicators was carried out using the Pearson Chi-square test (χ2), quantitative indicators using the Student’s or the Wilcoxon test between groups. Results The mean age (mean±SD) of the study patients was 51.07±7.45 years and the disease duration was 9.84±6.02 years. Most SARS-CoV-2 infected patients with gout exhibited a moderate illness (40.48%), almost every third (28.57%) had mild, 21.43% had severe and 9.52% had critical illness. Comparison of pre-COVID-19 vs 6-month post-COVID-19 data demonstrated an increase of gout flares in preceding 6 months (0.7±0.59 vs 4.35±2.25, p&lt;0.001), serum uric acid level (5.9±1.54 vs 7.62±1.99, p&lt;0.01), GAS (3.83±0.4 vs 6.1±1.63, p&lt;0.01), non-steroidal anti-inflammatory drug intake (19.05% vs 72.62%, p&lt;0.001), colchicine (27.38% vs 53.6%, p&lt;0.001), and corticosteroid use (5.95% vs 34.52%, p&lt;0.001), but decreased intake of ULT (88.09% vs 77.38%, p&gt;0.05), SF-36 PCS (43.7 ± 6.19 vs 36.08±6.54, p&lt;0.01) and SF-36 MCS (48.35±5.89 vs 40.13±6.84, p&lt;0.01). Conclusion The current study identified the majority of patients with gout had a moderate course, every fifth had a severe course and 9.52% had a critical course of COVID-19. In the post-COVID-19 period, we found a six-fold increase in gout flares, rising gout activity by 59.3%, more frequent medication use for symptomatic therapy of gout, decreased physical and mental health in the cohort of patients with gout. References [1]Dalbeth N, Robinson PC. Patients with gout: an under-recognised group at high risk of COVID-19. Lancet Rheumatol. 2021;3(5):e317-e318. doi:10.1016/S2665-9913(21)00073-4 Acknowledgements The authors express their gratitude to all of the healthcare workers from the Rheumatology Department of the Ternopil Regional Clinical Hospital for their commitment to patient care. Disclosure of Interests None declared